Holocene Advisors LP Acquires 416,562 Shares of The Cooper Companies, Inc. $COO

Holocene Advisors LP grew its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 25.6% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,046,700 shares of the medical device company’s stock after buying an additional 416,562 shares during the period. Holocene Advisors LP owned approximately 1.02% of Cooper Companies worth $145,643,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in COO. Horizon Investments LLC grew its position in Cooper Companies by 5.0% in the first quarter. Horizon Investments LLC now owns 2,859 shares of the medical device company’s stock worth $241,000 after acquiring an additional 136 shares in the last quarter. Wealth Alliance LLC lifted its stake in shares of Cooper Companies by 4.2% in the 2nd quarter. Wealth Alliance LLC now owns 4,230 shares of the medical device company’s stock valued at $301,000 after purchasing an additional 171 shares during the last quarter. State of Michigan Retirement System increased its position in shares of Cooper Companies by 0.4% during the 2nd quarter. State of Michigan Retirement System now owns 54,344 shares of the medical device company’s stock valued at $3,867,000 after purchasing an additional 200 shares during the last quarter. New York Life Investment Management LLC increased its position in shares of Cooper Companies by 0.7% during the 2nd quarter. New York Life Investment Management LLC now owns 30,019 shares of the medical device company’s stock valued at $2,136,000 after purchasing an additional 210 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Cooper Companies by 3.5% during the first quarter. EverSource Wealth Advisors LLC now owns 6,517 shares of the medical device company’s stock valued at $550,000 after buying an additional 220 shares during the period. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on COO. Barclays reiterated an “overweight” rating and set a $91.00 price objective on shares of Cooper Companies in a report on Monday. Stifel Nicolaus set a $95.00 price target on shares of Cooper Companies and gave the company a “buy” rating in a research note on Friday, December 5th. Citigroup reissued a “neutral” rating and issued a $88.00 price objective (up previously from $72.00) on shares of Cooper Companies in a research note on Monday. Weiss Ratings lowered Cooper Companies from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday. Finally, Robert W. Baird upped their target price on Cooper Companies from $85.00 to $98.00 and gave the stock an “outperform” rating in a report on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Cooper Companies presently has a consensus rating of “Moderate Buy” and an average price target of $90.15.

Cooper Companies Trading Down 0.0%

COO opened at $82.08 on Friday. The company has a current ratio of 1.89, a quick ratio of 1.13 and a debt-to-equity ratio of 0.30. The firm has a market cap of $16.09 billion, a price-to-earnings ratio of 43.66, a PEG ratio of 2.34 and a beta of 1.05. The Cooper Companies, Inc. has a 12 month low of $61.78 and a 12 month high of $100.24. The stock has a fifty day moving average price of $73.44 and a 200-day moving average price of $71.76.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, December 4th. The medical device company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.04. The company had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.06 billion. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter last year, the company earned $1.04 earnings per share. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. As a group, equities research analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies declared that its board has initiated a stock buyback program on Wednesday, September 17th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical device company to repurchase up to 15.4% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

Insider Activity

In other news, Director Lawrence Erik Kurzius acquired 2,000 shares of the business’s stock in a transaction dated Monday, September 29th. The shares were purchased at an average price of $68.39 per share, with a total value of $136,780.00. Following the transaction, the director directly owned 5,777 shares in the company, valued at approximately $395,089.03. This represents a 52.95% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.98% of the stock is currently owned by insiders.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.